11 completed, 7 terminated, 4 recruiting, 3 active not recruiting. 14 Phase 1, 12 Phase 2, 2 Early Phase 1.
Follow siplizumab: new trials by email Literature Review of siplizumab trials Research Report on siplizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant Siplizumab, Rabbit anti-thymocyte globulin - Renal Transplant Failure and Rejection | Phase 2 | Recruiting | Nefro Avillion Clinical Development, LLC | 120 | 2026-06-29 | 2026-10-06 |
| Tolerance Through Mixed Chimerism (Sip-Tego) Combined Kidney/Bone Marrow Transplant, Donation of Kidney / Bone Marrow, Conditioning Regimen (Rituxan, Siplizumab (or ATGAM), Cyclophosphamide, Tegoprubart) - Kidney Failure, Transplant Recipient (Kidney) | Early Phase 1 | Active not recruiting | Tatsuo Kawai, MD, PhD | 12 | 2025-05-31 | 2026-09-25 |
| Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa. Siplizumab - Hidradenitis Suppurativa | Early Phase 1 | Recruiting | University of Alabama at Birmingham | 12 | 2025-05-09 | 2026-09-01 |
| A Study of SIPLIZUMAB in AILD and LT Patients Siplizumab - Autoimmune Liver Disease, Liver Transplant Disorder | Phase 1 | Recruiting | Elizabeth C. Verna | 8 | 2024-09-11 | 2025-11-24 |
| A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients TCD601 - ALS | Phase 1 | Terminated | ITB-Med LLC | 7 | 2024-04-16 | 2026-07-17 |
| A Study of TCD601 in de Novo Renal Transplant Recipients TCD601, belatacept, ATG - Renal Transplantation | Phase 2 | Completed | ITB-Med LLC | 76 | 2023-12-28 | 2026-05-05 |
| Delayed Tolerance Through Mixed Chimerism Bone Marrow Transplant, Peripheral Blood Stem Cell Collection, Fludarabine - Kidney Failure, Kidney Transplant; Complications | Phase 1 / Phase 2 | Recruiting | Massachusetts General Hospital | 20 | 2023-10-01 | 2026-09-28 |
| Siplizumab for Sickle Cell Disease Transplant Siplizumab, Exchange Transfusion, Total Body Irradiation - Anemia, Sickle Cell | Phase 1 / Phase 2 | Terminated | Columbia University | 1 | 2023-09-28 | 2026-06-10 |
| Siplizumab in T1DM Siplizumab - Type 1 Diabetes Mellitus | Phase 1 / Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 8 | 2023-05-18 | 2026-07-28 |
| A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation TCD601, Cyclophosphamide, TAC - Liver Transplantation | Phase 2 | Active not recruiting | ITB-Med LLC | 12 | 2022-06-29 | 2024-11-27 |
| Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab, Combined bone marrow and kidney transplant - Renal Failure | Phase 1 | Active not recruiting | Massachusetts General Hospital | 20 | 2021-09-01 | 2026-09-28 |
| A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation TCD601, Tacrolimus (TAC), Corticosteroids (CS) - Kidney Transplantation | Phase 2 | Terminated | ITB-Med LLC | 33 | 2021-06-06 | 2026-03-12 |
| Renal Allograft Tolerance Through Mixed Chimerism MEDI-507, Rituximab, Total Body Irradiation - End Stage Renal Disease | Phase 1 / Phase 2 | Completed | Massachusetts General Hospital | 2 | 2013-03-01 | 2021-04-19 |
| Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas Rituximab, Etoposide, Siplizumab - T-Cell Peripheral Lymphoma, Gamma Delta Hepatosplenic T-Cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 15 | 2009-01-13 | 2021-11-03 |
| Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection Kidney Transplantation, Bone marrow transplantation, MEDI-507 - Kidney Transplantation, Kidney Failure, Chronic | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 5 | 2008-12-01 | 2015-11-10 |
| Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia MEDI-507 - Lymphoma, Leukemia | Phase 1 | Terminated | MedImmune LLC | 80 | 2005-02-01 | 2007-06-14 |
| Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease MEDI-507 - Lymphoproliferative Disorders | Phase 1 | Terminated | MedImmune LLC | 31 | 2004-04-01 | 2007-06-14 |
| Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies MEDI-507, Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant - Lymphoma, Leukemia | Phase 2 | Terminated | Massachusetts General Hospital | 14 | 2002-11-01 | 2018-03-16 |
| Long-Term Follow-Up Study of Psoriasis Patients Follow up from previous treatment with MEDI-507 - Psoriasis | Completed | MedImmune LLC | 200 | 2002-08-01 | 2008-09-22 | |
| A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis MEDI-507, Placebo - Plaque Psoriasis | Phase 2 | Completed | MedImmune LLC | 420 | 2001-09-01 | 2007-11-28 |
Showing 20 of 25. Sign in to see all of them.
Graft vs Host Disease (3) · Lymphoma (3) · Renal Insufficiency (3) · Kidney Failure, Chronic (2) · Leukemia (2) · Neoplasms (2) · Psoriasis (2) · Amyotrophic Lateral Sclerosis (1) · Anemia, Sickle Cell (1) · Cholangitis, Sclerosing (1) · Diabetes Mellitus, Type 1 (1) · Disease (1) · End Stage Liver Disease (1) · Hepatitis, Autoimmune (1) · Hidradenitis Suppurativa (1)
MedImmune LLC (9) · ITB-Med LLC (4) · Massachusetts General Hospital (4) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Columbia University (1) · Elizabeth C. Verna (1) · National Cancer Institute (NCI) (1) · Nefro Avillion Clinical Development, LLC (1) · Tatsuo Kawai, MD, PhD (1) · University of Alabama at Birmingham (1)
United States (22) · Sweden (3) · Canada (2) · Spain (2) · Austria (1) · Belgium (1) · Brazil (1) · France (1) · Germany (1) · Netherlands (1)
J. Bruce McClain, M.D. (3) · Fredrik Juhlin (2) · A. Benedict Cosimi, M.D. (1) · Barbara White, M.D. (1) · Ben Cosimi, MD (1) · Christine A Dingivan, M.D. (1) · David Sachs, M.D. (1) · David Sachs, MD (1) · Elizabeth Verna, MD (1) · Fredrik Julin (1) · John Janik, MD (1) · Karen Kaucic, MD (1) · Kellie Kennon, BSN (1) · Luz Hammershaimb, MD (1) · Markus Y Mapara, MD, PhD (1)